These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 19382304

  • 1. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I, Gergics P, Dabasi G, Igaz P, Racz K, Tulassay Z.
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract] [Full Text] [Related]

  • 2. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I, Gergics P, Dabasi G, Igaz P, Racz K, Tulassay Z.
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):386-7. PubMed ID: 20611009
    [No Abstract] [Full Text] [Related]

  • 3. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
    Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P.
    Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
    [Abstract] [Full Text] [Related]

  • 4. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
    Jianu CS, Fossmark R, Syversen U, Hauso Ø, Fykse V, Waldum HL.
    Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
    [Abstract] [Full Text] [Related]

  • 5. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS, Khuroo MS, Khuroo NS.
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [Abstract] [Full Text] [Related]

  • 6. Treatment of metastatic carcinoid tumours with octreotide.
    Ozbey N.
    Int J Clin Pract; 2002 Jun; 56(5):407. PubMed ID: 12137455
    [No Abstract] [Full Text] [Related]

  • 7. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
    Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB.
    J Surg Oncol; 2006 Apr 01; 93(5):368-72. PubMed ID: 16550587
    [Abstract] [Full Text] [Related]

  • 8. Multimodality treatment for gastric carcinoid tumor with liver metastases.
    Caplin ME, Hodgson HJ, Dhillon AP, Begent R, Buscombe J, Dick R, Rolles K, Burroughs AK.
    Am J Gastroenterol; 1998 Oct 01; 93(10):1945-8. PubMed ID: 9772061
    [Abstract] [Full Text] [Related]

  • 9. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
    Leong WL, Pasieka JL.
    J Surg Oncol; 2002 Mar 01; 79(3):180-7. PubMed ID: 11870669
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N, Herranz L, Alvarez C, Martínez Olmos MA, Márco A, Gómez-Pan A.
    Exp Clin Endocrinol Diabetes; 1998 Mar 01; 106(3):226-30. PubMed ID: 9710364
    [Abstract] [Full Text] [Related]

  • 11. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
    Yamashita K, Takase S, Nakamura T, Matsuda Y, Imanishi T, Sumi Y, Suzuki S, Kamigaki T, Ku Y, Kuroda D.
    Gan To Kagaku Ryoho; 2010 Nov 01; 37(12):2349-51. PubMed ID: 21224569
    [Abstract] [Full Text] [Related]

  • 12. [Clinical images in gastrology. Carcinoid tumor metastatic liver].
    Cortés-Espinosa T, de la Cruz-Guillén A, Manzano-Cortés H.
    Rev Gastroenterol Mex; 2008 Nov 01; 73(4):247. PubMed ID: 19666276
    [No Abstract] [Full Text] [Related]

  • 13. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
    Igaz P, Rácz K, Tulassay Z.
    Orv Hetil; 2007 Dec 09; 148(49):2343-6. PubMed ID: 18048114
    [Abstract] [Full Text] [Related]

  • 14. Carcinoid tumor regression with high-dose octreotide acetate: a patient report.
    Lokich J.
    Am J Clin Oncol; 1998 Jun 09; 21(3):246-7. PubMed ID: 9626790
    [Abstract] [Full Text] [Related]

  • 15. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
    Woltering EA, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G.
    Pancreas; 2006 Oct 09; 33(3):250-4. PubMed ID: 17003646
    [Abstract] [Full Text] [Related]

  • 16. [Analogs of somatostatin and carcinoid tumors].
    Gutiérrez Rodero F, Morales Cano JM, de Blas Laborda C, González Barber A.
    Med Clin (Barc); 1990 Jun 09; 95(2):78-9. PubMed ID: 2250512
    [No Abstract] [Full Text] [Related]

  • 17. The tumour vanishes.
    Todd JF, Meeran K.
    Clin Endocrinol (Oxf); 2000 Dec 09; 53(6):663-4. PubMed ID: 11155085
    [No Abstract] [Full Text] [Related]

  • 18. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
    Imtiaz KE, Monteith P, Khaleeli A.
    Clin Endocrinol (Oxf); 2000 Dec 09; 53(6):755-8. PubMed ID: 11155099
    [Abstract] [Full Text] [Related]

  • 19. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S, Corleto VD, Schillaci O, Moretti A, Panzuto F, Annibale B, Delle Fave G.
    Ital J Gastroenterol Hepatol; 1999 Dec 09; 31(1):23-7. PubMed ID: 10091100
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.